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Alzheimer’s disease (AD) is an age-related neurodegenerative disorder characterized by a progressive loss of memory and cognitive
skills. Although much attention has been devoted concerning the contribution of the microscopic lesions, senile plaques, and
neurofibrillary tangles to the disease process, inflammation has long been suspected to play a major role in the etiology of AD.
Recently, a novel variant in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) has been identified
that has refocused the spotlight back onto inflammation as amajor contributing factor in AD. Variants in TREM2 triple one’s risk of
developing late-onset AD. TREM2 is expressed onmicroglial cells, the residentmacrophages in the CNS, and functions to stimulate
phagocytosis on one hand and to suppress cytokine production and inflammation on the other hand.The purpose of this paper is to
discuss these recent developments including the potential role that TREM2 normally plays and how loss of functionmay contribute
to AD pathogenesis by enhancing oxidative stress and inflammation within the CNS. In this context, an overview of the pathways
linking beta-amyloid, neurofibrillary tangles (NFTs), oxidative stress, and inflammation will be discussed.
1. Defining Alzheimer’s Disease
Alzheimer’s disease (AD) is classified as a neurodegenerative
disorder affecting neurons of the brain that are responsible for
memory and higher cognitive functions. The brain consists
of over a 100-billion neurons that specialize in the ability to
transmit information to other cells, and thus constitute the
basic working unit of the brain. Because cortical neurons, in
general, do not have the capacity to regenerate, once neurons
are lost and symptoms manifest, the process is essentially
irreversible. In this manner, Alzheimer’s is classified as a
progressive neurodegenerative disease that can take any-
where from 5–20 years to run its course. The loss of these
neurons is significant with affected individuals losing up to
50% mass of the brain over the course of the disease. The
loss of these neurons leads to the symptoms of the disease
including memory impairments, difficulties with language,
inability to executemotor activities, and the overall decline in
cognitive skills [1]. Dementia is the umbrella term describing
the symptoms of AD, and AD is by far the leading cause of
dementia in the United States, being responsible for over 70%
of all known cases of dementia [2]. AD is a multifactorial
disorder, whose causes remain largely unknown. Despite
extensive research on genetic factors, the vast majority of
Alzheimer’s cases (>90%) are not directly linked to them
[3]. Aging is the most well-established risk factor for the
development of sporadic AD with incidence rates showing
an exponential growth between the ages of 65 and 85 years,
doubling every 5 years [3].
The national numbers on AD are alarming: currently one
in eight older Americans has AD making it the sixth leading
cause of death in the United States. An estimated 5.4 million
Americans have AD, a figure that includes 5.2 million people
age 65 and older [1]. Of those with AD, an estimated 4 percent
are under the age 65, 6 percent are 64 to 74, 44 percent are
75 to 84, and 46 percent are 85 or older [1]. Of all of the
major causes of death in the United States, including stroke,
cancer, and heart disease, only Alzheimer’s disease has shown
a significant increase inmortality during the same time frame
(2000–2008).
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Figure 1: The microscopic trouble makers in Alzheimer’s disease: senile plaques and neurofibrillary tangles. (a) In AD, widespread
accumulation of extracellular beta-amyloid plaques is evident (arrowhead), together with the presence of an abundance of NFTs along with
neuropil threads, which are composed principally of modified and aggregated tau (arrow). (b) For comparison purposes, an age-matched
control brain is depicted indicating a complete absence of plaques. However, it is not uncommon to find an occasional tangle (arrow) in the
normally aged brain although the numbers of tangles isminimal by comparison. Brain sections are representative staining of the hippocampus
using an anti-beta-amyloid antibody to label plaques (brown) and anti-PHF-1 (black) to label NFTs. Scale bars are 10 𝜇m.
2. Pathology Associated with AD
AD is diagnosed based upon the extent of senile plaques
composed of beta-amyloid andneurofibrillary tangles (NFTs)
containing abnormally phosphorylated and truncated tau [4].
The preponderance of research to date suggest a pivotal role
for beta-amyloid in the progression of AD, and collectively
this concept has coined the beta-amyloid hypothesis [5]. In
essence, this hypothesis stipulates that much of the pathology
associated with AD is driven by an increased load of beta-
amyloid in the brain of AD patients that can occur years
before the first symptoms of the disease manifest.
Beta-amyloid is formed following sequential cleavage of
the amyloid precursor protein (APP) by two proteases, 𝛽-
secretase and 𝛾-secretase. Once formed, beta-amyloid has
the propensity to self-aggregate into 𝛽-sheet structures that
deposit extracellularly forming senile plaques (Figure 1).
More recently, the beta-amyloid hypothesis has been modi-
fied to the “toxic beta-amyloid oligomer” hypothesis to rec-
oncile the apparent lack of correlation between beta-amyloid
in plaques and cognitive impairment [6]. This reformulation
of the amyloid cascade hypothesis focuses on oligomeric
aggregates of beta-amyloid as the prime toxic species causing
AD in part because this form of beta-amyloid strongly
correlates with the severity of dementia [7, 8]. In addition,
this oligomeric form of beta-amyloid is highly toxic and is the
trigger for the loss of synapses and neuronal damage [9, 10].
Given the strong support for the amyloid cascade hypothesis,
many of the current therapeutic strategies now in clinical
trials involve some aspect of modifying beta-amyloid pro-
duction or clearance [11]. However, despite the overwhelming
evidence supporting a role for beta-amyloid in AD, this
hypothesis is currently under critical assessment due to the
recent clinical trial failures based on the strategy of lowering
the beta-amyloid levels in the AD brain [12]. For example,
one strategy currently being investigated involves inhibit-
ing gamma-secretase to limit the production of the beta-
amyloid peptide derived from APP. One such compound,
semagacestat, showed promise in early clinical trials, but a
recent phase III trial involving over 2,600 participants was
discontinued after failure to demonstrate efficacy. Compared
to placebo, patients receiving semagacestat actually did worse
both in daily function and cognition and were at higher risk
of developing skin cancer [13].
The other major pathological finding in AD is the
presence of neurofibrillary tangles (NFTs) (Figure 1) [14].
NFTs are primarily composed of aggregated phosphorylated
tau protein and are a clinical feature not just in AD but
other diseases that are collectively referred to as “tauopathies”
[15]. Tau normally functions to help maintain the stability
of the cytoskeleton of neurons by binding to microtubules.
However, upon hyperphosphorylation and posttranslational
cleavage, tau loses its binding affinity for microtubules, lead-
ing to a destabilization of the cytoskeleton and self-assembly
of tau into tangles of paired helical filaments (PHFs) [16].
Although not universally accepted, it has been proposed that
NFTs may not be a central mediator of disease pathogenesis,
but instead, NFTs may actually serve a protective rather
than harmful function by providing a compensatory response
mounted by neurons against oxidative stress [17].
3. Mechanisms of Neurodegeneration in AD
According to the beta-amyloid hypothesis, the accumulation
and aggregation of beta-amyloid into toxic soluble oligomers
is the first step leading to neuronal degeneration in AD
[18]. Specifically, an important early molecular step is the
lost of synapses, which correlates highly with the initial
memory impairment observed in AD [19, 20]. Intensive
research over the last two decades has examined potential
pathways activated by beta-amyloid aggregates that lead
to synaptic dysfunction, NFT formation, and eventual cell
death. Figure 2 summarizes some of the major findings on
beta-amyloid-induced toxicity that begin with either beta-
amyloid activation of apoptotic pathways or promotion of
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Figure 2: Putative pathway for neurodegeneration in Alzheimer’s disease. According to the beta-amyloid hypothesis, the production of beta-
amyloid represents the first step in the entire process following the sequential cleavage of APP by 𝛽-secretase and 𝛾-secretase. Beta-amyloid
in turn may lead to NFT formation and eventual cell death by promoting oxidative stress and caspase activation through initiation of the
mitochondrial-mediated pathway of apoptosis.The activation of caspases results in cleavage of critical cellular proteins including tau, leading
to its modification and hyperphosphorylation, a key prerequisite for filament formation. See main text for details.
oxidative stress. With regards to apoptosis, since the early
nineties, studies have supported a general role for apoptosis in
AD [21–23]. In addition, the activation of caspases, including
caspase 3, 6, 8, and 9, has been documented in the AD
brain [24–30]. In turn, evidence suggests that once activated,
caspases may cleave critical cellular proteins in AD including
APP, actin, fodrin, glial acidic fibrillary protein, beclin-1, and
tau [28, 31–35]. Importantly, several studies have suggested
that caspase activation and cleavage of tau may precede and
contribute to the formation of NFTs [31, 32, 36].
An interlinking step between beta-amyloid and NFTs
could be the promotion of oxidative stress. Oxidative stress
either through lipid peroxidation or mitochondrial disrup-
tion is an early feature found in AD [37–39]. In addition,
oxidative stress may contribute to the activation of apoptosis
through both the extrinsic and intrinsic pathway [40, 41].
Finally, tau phosphorylation is upregulated by oxidative
stress [42] and tau filaments are modified by products of
oxidative stress [43–45]. Oxidative stress also activates several
kinases that have been implicated in the hyperphosphory-
lation of tau including glycogen synthase kinase-3 (GSK3),
Jun-N-terminal kinase (JNK), andmitogen-activated protein
kinases (MAPKs) [46, 47].
4. Inflammation in AD
Brain inflammation is a pathological hallmark of AD [48, 49].
In this regard, numerous studies have supported a definitive
role for inflammation in AD, with a key feature being the
presence of activated microglia [50–52] and reactive astro-
cytes found within senile plaques [53–55]. Epidemiological
studies have also pointed to inflammation as central to AD,
indicating that the long-term use of anti-inflammatory drugs
is linked with reduced risk of developing the disease [56].
Microglia are key players in mediating immune responses in
the CNS functioning as the resident macrophages of the CNS
and as such contribute to a healthy CNS by attacking and
removing potential pathogens and cell debris and by secreting
tissue rebuilding factors [57].
Interestingly, the link between the activation of microglia
and inflammation may be beta-amyloid. Thus, beta-amyloid
is a potent inducer of microglia activation [52, 58–60], and
one important role of microglia is to clear beta-amyloid
deposits out of the AD brain (for recent review, see [61]).
One potential caveat with inflammation is determining
cause and effect. Does AD cause inflammation? does the
dysregulation of immune system pathways trigger the disease
process? Alternatively, although chronic inflammation may
be a driving force in disease pathogenesis, it also may serve
as a beneficial response at least early on during the course
of AD. Finally, it is possible that inflammation could simply
be a byproduct of the disease process and may not effectively
alter its course. A recent discovery has now addressed this
issue and has unequivocally put inflammation in general and
specifically the microglial response center stage.
5. Triggering Receptor Expressed on Myeloid
Cells 2 (TREM2)
TREM2 is expressed on the cell membrane of many types
of immune cells including macrophages, dendritic cells,
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osteoclasts, and microglia [62]. TREM2 is thought to act as
a cell surface receptor, and although the endogenous ligand
has yet to be identified, it is known that it requires the adaptor
protein 12 (DAP12) for the initiation of signaling cascades
[63]. Activation of the TREM2 receptor on microglia has two
important function consequences: (1) stimulation of phago-
cytosis activity and (2) decreasedmicroglial proinflammatory
responses [64]. Collectively, TREM2 may function to help
aid microglia to clear damaged or apoptotic cells and cellular
debris and help resolve damage-induced inflammation.
Insights into the important role that TREM2 plays
have been deduced from individuals harboring homozygous
mutations in the TREM2 gene. Such a mutation leads to
The Nasu-Hakola disease, which manifests as a combination
of bone cysts and dementia [65]. Affected individuals show
progressive inflammatory neurodegeneration with loss of
white matter and cystic bone lesions followed by death by the
fifth decade of life [66].
Further support for TREM2 being an importantmediator
in neuroinflammation comes from animal models of mul-
tiple sclerosis (MS). Two different studies have reported a
protective role of TREM2. In one study, blockade of TREM2
function enhanced disease progression in an experimental
murine model of autoimmune encephalomyelitis [67]. In the
second study, intravenous application of TREM2-transduced
myeloid cells limited tissue destruction and facilitated repair
in a murine model of MS [68]. Taken together, these studies
highlight a critical role for TREM2 during inflammatory
responses in the CNS.
6. TREM2 in Alzheimer’s Disease
TREM2 functionmay affect AD pathology through phagocy-
tosis. In amurinemodel of AD, Frank et al. demonstrated that
TREM2 is upregulated in microglia found at the border of
amyloid plaque deposits [69]. Moreover, TREM2 expression
has been positively correlated with the phagocytic clearance
of beta-amyloid in APP transgenic mice [70]. Given the
well-documented role that microglia play in removing beta-
amyloid [61], the expression of TREM2 by beta-amyloid
plaque-associatedmicrogliamay be interpreted as an effort to
enhance beta-amyloid clearance and to limit the proinflam-
matory cytokine expression in response to microglia acti-
vation by beta-amyloid itself. Besides clearing beta-amyloid,
TREM2 may also function to remove debris and participate
in synapse remodeling [71].
The strongest evidence to date supporting a role for
inflammation in AD comes from two recent studies demon-
strating that TREM2 variants increase the risk for AD
approximately 3-fold [72, 73]. These studies indicated that
individuals that are heterozygous for several TREM2 muta-
tions (the most common variant being a R47H change) were
at a greater risk for AD. In addition, Jonsson and colleagues
also showed that elderly carriers of the TREM2 variant who
were asymptomatic for AD, nevertheless, performed worse
in cognitive exams as compared to noncarriers [72]. It is
noteworthy that this particular mutation is extremely rare,
only being found at a frequency of 0.63 percent. Compare this
to the greatest risk factor for late-onset AD, the apoE4 allele,
in which it has been estimated that approximately 40% of AD
subjects currently harbor at least one copy of this allele [74].
Interestingly, it is only individuals that are heterozygous
for TREM2 that are at risk for AD: homozygous, autosomal
recessive mutations for TREM2 result in The Nasu-Hakola
disease in some individuals characterized by bone cysts and
dementia [75], while resulting in fronttemporal dementia
without bone disease in others [76]. Due to the common
thread of dementia in these homozygous mutations, it was
these initial findings that spurred further research to search
for heterozygous mutations in the TREM2 gene in AD
subjects.
Given the prophagocytic role of TREM2, loss of phago-
cytic activity of microglia could represent one mechanism by
which the TREM2 mutations increased the risk to develop
AD (Figure 3). Because TREM2 functions in microglia to
also dampen microglial activation, mutations and loss of
function could result in runaway inflammation as well. Based
on these results, it is tempting to speculate on the potential
pharmacological value that TREM2 agonists might have in
AD. Future directions should answer this question as well as
the possibility of finding more rare variants that have similar
effects, including those in DAP12 and TREM2’s intracellular
signaling partner.
7. Concluding Remarks
Research in the field of AD has uncovered the detailed
molecular mechanisms leading to the hallmark, microscopic
lesions consisting of beta-amyloid plaques and NFTs. How-
ever, how these lesions lead to neurodegeneration is still
under investigation. An important consideration in this
paper was the attempt to unify the various potential players
that contribute to cell death in AD, including beta-amyloid,
NFTs, caspases, oxidative stress, and inflammation. In this
regard, it is suggested that beta-amyloid in the form of
soluble beta-amyloid oligomers represents the earliest known
step in the entire process, setting off a chain of events that
ultimately lead to chronic inflammation and neuronal cell
death. It has been difficult to assess the cause and effect
relationship of inflammation in AD, but the recent discovery
of the TREM2 mutations has now put inflammation back
on center stage as a process that contributes to disease
progression. This is highlighted by the data indicating an
approximate 3-fold increase in the risk for AD in individuals
harboring heterozygous variants in the TREM2 gene. Because
TREM2 functions to modulate the inflammatory immune
responses in microglia, mutations in this gene, in turn,
could contribute to disease pathogenesis by preventing the
clearance of beta-amyloid deposits and/or by enhancing
inflammation. However, because the function of TREM2
is still poorly understood, it is difficult to determine how
loss of TREM2 function might contribute to the disease
process. Future studies examining a direct role for TREM2
in AD should help shed light on this question and provide
further support for the role of chronic inflammation in this
disease.
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Figure 3: A central role for microglia in Alzheimer’s disease is dependent upon a functional TREM2 receptor. Microglia represent one of the
three classes of glia cells, whose primary function is to act as a major line of active immune defense in the CNS. In AD, microglia (top) and
astrocytes (bottom) function in phagocytosis and in this regard help clear the brain of beta-amyloid deposits and apoptotic cells as well as any
cellular debris. The important actions of microglia appear to be mediated through activation of the TREM2 receptor whose few known roles
include suppressing inflammation and stimulating phagocytosis. As shown recently, variants in the TREM2 receptor have been discovered,
and it has been suggested that the change in sequence leads to a loss of receptor function. It has been hypothesized that the loss of TREM2
activity has two major consequences: (1) decreased ability of microglia to remove extracellular deposits of beta-amyloid and (2) enhanced
neuroinflammation. The loss of TREM2 function and altered immune responses by microglia may explain the increased risk for AD for
individuals carrying the heterozygous mutations in TREM2.
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